CONTACT US NEXALIS THERAPEUTICS T: +61 3 9070 1221 | E: investors@nexalistherapeutics.com | W: https://www.nexalistherapeutics.com 1 31 July 2026 Quarter ended 30 June 2026 Melbourne, Australia – Nexalis Therapeutics Ltd (ASX: NX1), (‘ Nexalis...
Jun26 Quarterly Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
Story so far
Earlier from Nexalis Therapeutics
- Change in substantial holding
- Update on Funding Facility and Clinical Program
- Binding Letter of Intent to replace existing $53m facility
- Suspension from Quotation
- Mar26 Appendix 4C Cash Flow Report
Later from Nexalis Therapeutics
- Jun26 Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Removal of draft wording in the directors report HY accounts
- Chair Appointment/Resignation
- Initial Director's Interest Notice - Niv Dagan
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics